Frontiers in Pharmacology-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=1003537, encodeId=7ed3100353e7d, content=偏重的研究方向：心血管药理学 经验分享：请问朋友们，frontiers in pharmacology这个杂志社需不需要原始数据啊，我的文章现在处于Review Finalized，两个审稿人均已同意收稿，但是编辑提了不少问题。目前为止还未通知我上传原始记录，我想问下会要吗？大概什么时候要？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=38205516444, createdName=若氵离, createdTime=Thu Jul 29 10:20:59 CST 2021, time=2021-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1247445, encodeId=b238124e445bc, content=偏重的研究方向：民族药理学;中药复方 经验分享：投稿第三天就收到上传原始数据的邮箱了。实验结果的原始数据好好，第一次遇到连把数据库下载的原始数据也要提供😄, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=223, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Tue Sep 06 12:10:42 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2133754, encodeId=26252133e54f1, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：综述 经验分享：09 May 2023 Article accepted for publication. 02 May 2023 Review of Review Editor 3 finalized. 28 Apr 2023 Submitting Author posted new comments in the Editor tab. Submitting Author re-submitted manuscript. You posted new comments. 16 Apr 2023 Reviewer 3 posted new comments. 15 Apr 2023 Submitting Author re-submitted manuscript. You posted new comments. Submitting Author posted new comments in the Editor tab. 06 Apr 2023 Interactive review forum activated. 05 Apr 2023 Review of Reviewer 1 is finalized. 04 Apr 2023 Review of Reviewer 2 is finalized. 23 Mar 2023 Submitting Author submitted manuscrip, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64f46563607, createdName=ms1000000861767492, createdTime=Sun May 14 16:38:06 CST 2023, time=2023-05-14, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2148044, encodeId=cfd7214804414, content=审稿速度:2.0 偏重的研究方向：药理 经验分享：从投稿到接收整整两个月，非常顺利的一次投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e82b8691518, createdName=ms2000000241844584, createdTime=Fri Jul 14 17:07:22 CST 2023, time=2023-07-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2146235, encodeId=229a21462355e, content=大佬们，请问接收后多久能在web of science检索到, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=31455446726, createdName=ms4000001861684629, createdTime=Tue Jul 04 08:51:52 CST 2023, time=2023-07-04, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2145782, encodeId=622a2145e828b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：中药单体 经验分享：历时2个月，4个审稿人，一个拒稿，三个修改后同意。 20 Jun 2023 Article accepted for publication. 16 Jun 2023 Review of Review Editor 3 finalized. 13 Jun 2023 Corresponding Author re-submitted manuscript. 12 Jun 2023 Reviewer 3 posted new comments. 10 Jun 2023 Review of Review Editor 4 finalized. 09 Jun 2023 Review of Review Editor 2 finalized.Review Editor 1 posted new comments.Corresponding Author re-submitted manuscript.You posted new comments.You posted new comments.You posted new comments. 29 May 2023 Editorial Office reminded you to respond to reviewer 3 and/or resubmit your manuscript in the discussion forum. 16 May 2023 Associate Editor reactivated the review of Review Editor 3.Interactive review forum activated. 11 May 2023 Review of Reviewer 3 is finalized. 03 May 2023 Corresponding Author submitted manuscript , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=31455446726, createdName=ms4000001861684629, createdTime=Sat Jul 01 09:37:31 CST 2023, time=2023-07-01, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2145328, encodeId=91c621453289a, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：中药药理学;药理学;肿瘤药理 经验分享：2023年5.6分，不错，点赞！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:38:18 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2129824, encodeId=9267212982410, content=偏重的研究方向：中药药理 经验分享：请问一般有几个审稿人呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01228365434, createdName=ms5000001535986025, createdTime=Wed May 03 10:58:41 CST 2023, time=2023-05-03, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2108610, encodeId=55da210861019, content=The Associate Editor X is evaluating any revisions made to the manuscript to take a final decision.这个状态需要多久？还会被拒稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50135526541, createdName=ms3000000979708654, createdTime=Tue Jan 03 11:40:19 CST 2023, time=2023-01-03, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2099025, encodeId=bca6209902562, content=请问大家在Editorial Assignment阶段都停留多久呀，我的马上1个月了也没有动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39605645778, createdName=ms3000001177178927, createdTime=Mon Nov 07 18:58:58 CST 2022, time=2022-11-07, status=1, ipAttribution=)]

2021-07-29 若氵离

偏重的研究方向：心血管药理学
经验分享：请问朋友们，frontiers in pharmacology这个杂志社需不需要原始数据啊，我的文章现在处于Review Finalized，两个审稿人均已同意收稿，但是编辑提了不少问题。目前为止还未通知我上传原始记录，我想问下会要吗？大概什么时候要？

76 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=1003537, encodeId=7ed3100353e7d, content=偏重的研究方向：心血管药理学 经验分享：请问朋友们，frontiers in pharmacology这个杂志社需不需要原始数据啊，我的文章现在处于Review Finalized，两个审稿人均已同意收稿，但是编辑提了不少问题。目前为止还未通知我上传原始记录，我想问下会要吗？大概什么时候要？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=38205516444, createdName=若氵离, createdTime=Thu Jul 29 10:20:59 CST 2021, time=2021-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1247445, encodeId=b238124e445bc, content=偏重的研究方向：民族药理学;中药复方 经验分享：投稿第三天就收到上传原始数据的邮箱了。实验结果的原始数据好好，第一次遇到连把数据库下载的原始数据也要提供😄, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=223, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Tue Sep 06 12:10:42 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2133754, encodeId=26252133e54f1, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：综述 经验分享：09 May 2023 Article accepted for publication. 02 May 2023 Review of Review Editor 3 finalized. 28 Apr 2023 Submitting Author posted new comments in the Editor tab. Submitting Author re-submitted manuscript. You posted new comments. 16 Apr 2023 Reviewer 3 posted new comments. 15 Apr 2023 Submitting Author re-submitted manuscript. You posted new comments. Submitting Author posted new comments in the Editor tab. 06 Apr 2023 Interactive review forum activated. 05 Apr 2023 Review of Reviewer 1 is finalized. 04 Apr 2023 Review of Reviewer 2 is finalized. 23 Mar 2023 Submitting Author submitted manuscrip, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64f46563607, createdName=ms1000000861767492, createdTime=Sun May 14 16:38:06 CST 2023, time=2023-05-14, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2148044, encodeId=cfd7214804414, content=审稿速度:2.0 偏重的研究方向：药理 经验分享：从投稿到接收整整两个月，非常顺利的一次投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e82b8691518, createdName=ms2000000241844584, createdTime=Fri Jul 14 17:07:22 CST 2023, time=2023-07-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2146235, encodeId=229a21462355e, content=大佬们，请问接收后多久能在web of science检索到, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=31455446726, createdName=ms4000001861684629, createdTime=Tue Jul 04 08:51:52 CST 2023, time=2023-07-04, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2145782, encodeId=622a2145e828b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：中药单体 经验分享：历时2个月，4个审稿人，一个拒稿，三个修改后同意。 20 Jun 2023 Article accepted for publication. 16 Jun 2023 Review of Review Editor 3 finalized. 13 Jun 2023 Corresponding Author re-submitted manuscript. 12 Jun 2023 Reviewer 3 posted new comments. 10 Jun 2023 Review of Review Editor 4 finalized. 09 Jun 2023 Review of Review Editor 2 finalized.Review Editor 1 posted new comments.Corresponding Author re-submitted manuscript.You posted new comments.You posted new comments.You posted new comments. 29 May 2023 Editorial Office reminded you to respond to reviewer 3 and/or resubmit your manuscript in the discussion forum. 16 May 2023 Associate Editor reactivated the review of Review Editor 3.Interactive review forum activated. 11 May 2023 Review of Reviewer 3 is finalized. 03 May 2023 Corresponding Author submitted manuscript , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=31455446726, createdName=ms4000001861684629, createdTime=Sat Jul 01 09:37:31 CST 2023, time=2023-07-01, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2145328, encodeId=91c621453289a, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：中药药理学;药理学;肿瘤药理 经验分享：2023年5.6分，不错，点赞！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:38:18 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2129824, encodeId=9267212982410, content=偏重的研究方向：中药药理 经验分享：请问一般有几个审稿人呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01228365434, createdName=ms5000001535986025, createdTime=Wed May 03 10:58:41 CST 2023, time=2023-05-03, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2108610, encodeId=55da210861019, content=The Associate Editor X is evaluating any revisions made to the manuscript to take a final decision.这个状态需要多久？还会被拒稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50135526541, createdName=ms3000000979708654, createdTime=Tue Jan 03 11:40:19 CST 2023, time=2023-01-03, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2099025, encodeId=bca6209902562, content=请问大家在Editorial Assignment阶段都停留多久呀，我的马上1个月了也没有动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39605645778, createdName=ms3000001177178927, createdTime=Mon Nov 07 18:58:58 CST 2022, time=2022-11-07, status=1, ipAttribution=)]

2022-09-06 ms4000001680289394

偏重的研究方向：民族药理学;中药复方
经验分享：投稿第三天就收到上传原始数据的邮箱了。实验结果的原始数据好好，第一次遇到连把数据库下载的原始数据也要提供😄

223 12

展开12条回复

[GetPortalCommentsPageByObjectIdResponse(id=1003537, encodeId=7ed3100353e7d, content=偏重的研究方向：心血管药理学 经验分享：请问朋友们，frontiers in pharmacology这个杂志社需不需要原始数据啊，我的文章现在处于Review Finalized，两个审稿人均已同意收稿，但是编辑提了不少问题。目前为止还未通知我上传原始记录，我想问下会要吗？大概什么时候要？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=38205516444, createdName=若氵离, createdTime=Thu Jul 29 10:20:59 CST 2021, time=2021-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1247445, encodeId=b238124e445bc, content=偏重的研究方向：民族药理学;中药复方 经验分享：投稿第三天就收到上传原始数据的邮箱了。实验结果的原始数据好好，第一次遇到连把数据库下载的原始数据也要提供😄, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=223, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Tue Sep 06 12:10:42 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2133754, encodeId=26252133e54f1, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：综述 经验分享：09 May 2023 Article accepted for publication. 02 May 2023 Review of Review Editor 3 finalized. 28 Apr 2023 Submitting Author posted new comments in the Editor tab. Submitting Author re-submitted manuscript. You posted new comments. 16 Apr 2023 Reviewer 3 posted new comments. 15 Apr 2023 Submitting Author re-submitted manuscript. You posted new comments. Submitting Author posted new comments in the Editor tab. 06 Apr 2023 Interactive review forum activated. 05 Apr 2023 Review of Reviewer 1 is finalized. 04 Apr 2023 Review of Reviewer 2 is finalized. 23 Mar 2023 Submitting Author submitted manuscrip, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64f46563607, createdName=ms1000000861767492, createdTime=Sun May 14 16:38:06 CST 2023, time=2023-05-14, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2148044, encodeId=cfd7214804414, content=审稿速度:2.0 偏重的研究方向：药理 经验分享：从投稿到接收整整两个月，非常顺利的一次投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e82b8691518, createdName=ms2000000241844584, createdTime=Fri Jul 14 17:07:22 CST 2023, time=2023-07-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2146235, encodeId=229a21462355e, content=大佬们，请问接收后多久能在web of science检索到, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=31455446726, createdName=ms4000001861684629, createdTime=Tue Jul 04 08:51:52 CST 2023, time=2023-07-04, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2145782, encodeId=622a2145e828b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：中药单体 经验分享：历时2个月，4个审稿人，一个拒稿，三个修改后同意。 20 Jun 2023 Article accepted for publication. 16 Jun 2023 Review of Review Editor 3 finalized. 13 Jun 2023 Corresponding Author re-submitted manuscript. 12 Jun 2023 Reviewer 3 posted new comments. 10 Jun 2023 Review of Review Editor 4 finalized. 09 Jun 2023 Review of Review Editor 2 finalized.Review Editor 1 posted new comments.Corresponding Author re-submitted manuscript.You posted new comments.You posted new comments.You posted new comments. 29 May 2023 Editorial Office reminded you to respond to reviewer 3 and/or resubmit your manuscript in the discussion forum. 16 May 2023 Associate Editor reactivated the review of Review Editor 3.Interactive review forum activated. 11 May 2023 Review of Reviewer 3 is finalized. 03 May 2023 Corresponding Author submitted manuscript , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=31455446726, createdName=ms4000001861684629, createdTime=Sat Jul 01 09:37:31 CST 2023, time=2023-07-01, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2145328, encodeId=91c621453289a, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：中药药理学;药理学;肿瘤药理 经验分享：2023年5.6分，不错，点赞！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:38:18 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2129824, encodeId=9267212982410, content=偏重的研究方向：中药药理 经验分享：请问一般有几个审稿人呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01228365434, createdName=ms5000001535986025, createdTime=Wed May 03 10:58:41 CST 2023, time=2023-05-03, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2108610, encodeId=55da210861019, content=The Associate Editor X is evaluating any revisions made to the manuscript to take a final decision.这个状态需要多久？还会被拒稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50135526541, createdName=ms3000000979708654, createdTime=Tue Jan 03 11:40:19 CST 2023, time=2023-01-03, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2099025, encodeId=bca6209902562, content=请问大家在Editorial Assignment阶段都停留多久呀，我的马上1个月了也没有动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39605645778, createdName=ms3000001177178927, createdTime=Mon Nov 07 18:58:58 CST 2022, time=2022-11-07, status=1, ipAttribution=)]

2023-05-14 ms1000000861767492 来自吉林省

审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向：综述
经验分享：09 May 2023
Article accepted for publication.
02 May 2023
Review of Review Editor 3 finalized.
28 Apr 2023
Submitting Author posted new comments in the Editor tab.
Submitting Author re-submitted manuscript.
You posted new comments.
16 Apr 2023
Reviewer 3 posted new comments.
15 Apr 2023
Submitting Author re-submitted manuscript.
You posted new comments.
Submitting Author posted new comments in the Editor tab.
06 Apr 2023
Interactive review forum activated.
05 Apr 2023
Review of Reviewer 1 is finalized.
04 Apr 2023
Review of Reviewer 2 is finalized.
23 Mar 2023
Submitting Author submitted manuscrip

93 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=1003537, encodeId=7ed3100353e7d, content=偏重的研究方向：心血管药理学 经验分享：请问朋友们，frontiers in pharmacology这个杂志社需不需要原始数据啊，我的文章现在处于Review Finalized，两个审稿人均已同意收稿，但是编辑提了不少问题。目前为止还未通知我上传原始记录，我想问下会要吗？大概什么时候要？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=38205516444, createdName=若氵离, createdTime=Thu Jul 29 10:20:59 CST 2021, time=2021-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1247445, encodeId=b238124e445bc, content=偏重的研究方向：民族药理学;中药复方 经验分享：投稿第三天就收到上传原始数据的邮箱了。实验结果的原始数据好好，第一次遇到连把数据库下载的原始数据也要提供😄, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=223, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Tue Sep 06 12:10:42 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2133754, encodeId=26252133e54f1, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：综述 经验分享：09 May 2023 Article accepted for publication. 02 May 2023 Review of Review Editor 3 finalized. 28 Apr 2023 Submitting Author posted new comments in the Editor tab. Submitting Author re-submitted manuscript. You posted new comments. 16 Apr 2023 Reviewer 3 posted new comments. 15 Apr 2023 Submitting Author re-submitted manuscript. You posted new comments. Submitting Author posted new comments in the Editor tab. 06 Apr 2023 Interactive review forum activated. 05 Apr 2023 Review of Reviewer 1 is finalized. 04 Apr 2023 Review of Reviewer 2 is finalized. 23 Mar 2023 Submitting Author submitted manuscrip, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64f46563607, createdName=ms1000000861767492, createdTime=Sun May 14 16:38:06 CST 2023, time=2023-05-14, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2148044, encodeId=cfd7214804414, content=审稿速度:2.0 偏重的研究方向：药理 经验分享：从投稿到接收整整两个月，非常顺利的一次投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e82b8691518, createdName=ms2000000241844584, createdTime=Fri Jul 14 17:07:22 CST 2023, time=2023-07-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2146235, encodeId=229a21462355e, content=大佬们，请问接收后多久能在web of science检索到, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=31455446726, createdName=ms4000001861684629, createdTime=Tue Jul 04 08:51:52 CST 2023, time=2023-07-04, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2145782, encodeId=622a2145e828b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：中药单体 经验分享：历时2个月，4个审稿人，一个拒稿，三个修改后同意。 20 Jun 2023 Article accepted for publication. 16 Jun 2023 Review of Review Editor 3 finalized. 13 Jun 2023 Corresponding Author re-submitted manuscript. 12 Jun 2023 Reviewer 3 posted new comments. 10 Jun 2023 Review of Review Editor 4 finalized. 09 Jun 2023 Review of Review Editor 2 finalized.Review Editor 1 posted new comments.Corresponding Author re-submitted manuscript.You posted new comments.You posted new comments.You posted new comments. 29 May 2023 Editorial Office reminded you to respond to reviewer 3 and/or resubmit your manuscript in the discussion forum. 16 May 2023 Associate Editor reactivated the review of Review Editor 3.Interactive review forum activated. 11 May 2023 Review of Reviewer 3 is finalized. 03 May 2023 Corresponding Author submitted manuscript , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=31455446726, createdName=ms4000001861684629, createdTime=Sat Jul 01 09:37:31 CST 2023, time=2023-07-01, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2145328, encodeId=91c621453289a, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：中药药理学;药理学;肿瘤药理 经验分享：2023年5.6分，不错，点赞！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:38:18 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2129824, encodeId=9267212982410, content=偏重的研究方向：中药药理 经验分享：请问一般有几个审稿人呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01228365434, createdName=ms5000001535986025, createdTime=Wed May 03 10:58:41 CST 2023, time=2023-05-03, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2108610, encodeId=55da210861019, content=The Associate Editor X is evaluating any revisions made to the manuscript to take a final decision.这个状态需要多久？还会被拒稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50135526541, createdName=ms3000000979708654, createdTime=Tue Jan 03 11:40:19 CST 2023, time=2023-01-03, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2099025, encodeId=bca6209902562, content=请问大家在Editorial Assignment阶段都停留多久呀，我的马上1个月了也没有动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39605645778, createdName=ms3000001177178927, createdTime=Mon Nov 07 18:58:58 CST 2022, time=2022-11-07, status=1, ipAttribution=)]

2023-07-14 ms2000000241844584 来自北京

审稿速度:2.0
偏重的研究方向：药理
经验分享：从投稿到接收整整两个月，非常顺利的一次投稿

65 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1003537, encodeId=7ed3100353e7d, content=偏重的研究方向：心血管药理学 经验分享：请问朋友们，frontiers in pharmacology这个杂志社需不需要原始数据啊，我的文章现在处于Review Finalized，两个审稿人均已同意收稿，但是编辑提了不少问题。目前为止还未通知我上传原始记录，我想问下会要吗？大概什么时候要？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=38205516444, createdName=若氵离, createdTime=Thu Jul 29 10:20:59 CST 2021, time=2021-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1247445, encodeId=b238124e445bc, content=偏重的研究方向：民族药理学;中药复方 经验分享：投稿第三天就收到上传原始数据的邮箱了。实验结果的原始数据好好，第一次遇到连把数据库下载的原始数据也要提供😄, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=223, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Tue Sep 06 12:10:42 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2133754, encodeId=26252133e54f1, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：综述 经验分享：09 May 2023 Article accepted for publication. 02 May 2023 Review of Review Editor 3 finalized. 28 Apr 2023 Submitting Author posted new comments in the Editor tab. Submitting Author re-submitted manuscript. You posted new comments. 16 Apr 2023 Reviewer 3 posted new comments. 15 Apr 2023 Submitting Author re-submitted manuscript. You posted new comments. Submitting Author posted new comments in the Editor tab. 06 Apr 2023 Interactive review forum activated. 05 Apr 2023 Review of Reviewer 1 is finalized. 04 Apr 2023 Review of Reviewer 2 is finalized. 23 Mar 2023 Submitting Author submitted manuscrip, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64f46563607, createdName=ms1000000861767492, createdTime=Sun May 14 16:38:06 CST 2023, time=2023-05-14, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2148044, encodeId=cfd7214804414, content=审稿速度:2.0 偏重的研究方向：药理 经验分享：从投稿到接收整整两个月，非常顺利的一次投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e82b8691518, createdName=ms2000000241844584, createdTime=Fri Jul 14 17:07:22 CST 2023, time=2023-07-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2146235, encodeId=229a21462355e, content=大佬们，请问接收后多久能在web of science检索到, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=31455446726, createdName=ms4000001861684629, createdTime=Tue Jul 04 08:51:52 CST 2023, time=2023-07-04, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2145782, encodeId=622a2145e828b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：中药单体 经验分享：历时2个月，4个审稿人，一个拒稿，三个修改后同意。 20 Jun 2023 Article accepted for publication. 16 Jun 2023 Review of Review Editor 3 finalized. 13 Jun 2023 Corresponding Author re-submitted manuscript. 12 Jun 2023 Reviewer 3 posted new comments. 10 Jun 2023 Review of Review Editor 4 finalized. 09 Jun 2023 Review of Review Editor 2 finalized.Review Editor 1 posted new comments.Corresponding Author re-submitted manuscript.You posted new comments.You posted new comments.You posted new comments. 29 May 2023 Editorial Office reminded you to respond to reviewer 3 and/or resubmit your manuscript in the discussion forum. 16 May 2023 Associate Editor reactivated the review of Review Editor 3.Interactive review forum activated. 11 May 2023 Review of Reviewer 3 is finalized. 03 May 2023 Corresponding Author submitted manuscript , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=31455446726, createdName=ms4000001861684629, createdTime=Sat Jul 01 09:37:31 CST 2023, time=2023-07-01, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2145328, encodeId=91c621453289a, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：中药药理学;药理学;肿瘤药理 经验分享：2023年5.6分，不错，点赞！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:38:18 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2129824, encodeId=9267212982410, content=偏重的研究方向：中药药理 经验分享：请问一般有几个审稿人呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01228365434, createdName=ms5000001535986025, createdTime=Wed May 03 10:58:41 CST 2023, time=2023-05-03, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2108610, encodeId=55da210861019, content=The Associate Editor X is evaluating any revisions made to the manuscript to take a final decision.这个状态需要多久？还会被拒稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50135526541, createdName=ms3000000979708654, createdTime=Tue Jan 03 11:40:19 CST 2023, time=2023-01-03, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2099025, encodeId=bca6209902562, content=请问大家在Editorial Assignment阶段都停留多久呀，我的马上1个月了也没有动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39605645778, createdName=ms3000001177178927, createdTime=Mon Nov 07 18:58:58 CST 2022, time=2022-11-07, status=1, ipAttribution=)]

2023-07-04 ms4000001861684629 来自黑龙江省

大佬们，请问接收后多久能在web of science检索到

77 0

[GetPortalCommentsPageByObjectIdResponse(id=1003537, encodeId=7ed3100353e7d, content=偏重的研究方向：心血管药理学 经验分享：请问朋友们，frontiers in pharmacology这个杂志社需不需要原始数据啊，我的文章现在处于Review Finalized，两个审稿人均已同意收稿，但是编辑提了不少问题。目前为止还未通知我上传原始记录，我想问下会要吗？大概什么时候要？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=38205516444, createdName=若氵离, createdTime=Thu Jul 29 10:20:59 CST 2021, time=2021-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1247445, encodeId=b238124e445bc, content=偏重的研究方向：民族药理学;中药复方 经验分享：投稿第三天就收到上传原始数据的邮箱了。实验结果的原始数据好好，第一次遇到连把数据库下载的原始数据也要提供😄, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=223, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Tue Sep 06 12:10:42 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2133754, encodeId=26252133e54f1, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：综述 经验分享：09 May 2023 Article accepted for publication. 02 May 2023 Review of Review Editor 3 finalized. 28 Apr 2023 Submitting Author posted new comments in the Editor tab. Submitting Author re-submitted manuscript. You posted new comments. 16 Apr 2023 Reviewer 3 posted new comments. 15 Apr 2023 Submitting Author re-submitted manuscript. You posted new comments. Submitting Author posted new comments in the Editor tab. 06 Apr 2023 Interactive review forum activated. 05 Apr 2023 Review of Reviewer 1 is finalized. 04 Apr 2023 Review of Reviewer 2 is finalized. 23 Mar 2023 Submitting Author submitted manuscrip, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64f46563607, createdName=ms1000000861767492, createdTime=Sun May 14 16:38:06 CST 2023, time=2023-05-14, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2148044, encodeId=cfd7214804414, content=审稿速度:2.0 偏重的研究方向：药理 经验分享：从投稿到接收整整两个月，非常顺利的一次投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e82b8691518, createdName=ms2000000241844584, createdTime=Fri Jul 14 17:07:22 CST 2023, time=2023-07-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2146235, encodeId=229a21462355e, content=大佬们，请问接收后多久能在web of science检索到, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=31455446726, createdName=ms4000001861684629, createdTime=Tue Jul 04 08:51:52 CST 2023, time=2023-07-04, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2145782, encodeId=622a2145e828b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：中药单体 经验分享：历时2个月，4个审稿人，一个拒稿，三个修改后同意。 20 Jun 2023 Article accepted for publication. 16 Jun 2023 Review of Review Editor 3 finalized. 13 Jun 2023 Corresponding Author re-submitted manuscript. 12 Jun 2023 Reviewer 3 posted new comments. 10 Jun 2023 Review of Review Editor 4 finalized. 09 Jun 2023 Review of Review Editor 2 finalized.Review Editor 1 posted new comments.Corresponding Author re-submitted manuscript.You posted new comments.You posted new comments.You posted new comments. 29 May 2023 Editorial Office reminded you to respond to reviewer 3 and/or resubmit your manuscript in the discussion forum. 16 May 2023 Associate Editor reactivated the review of Review Editor 3.Interactive review forum activated. 11 May 2023 Review of Reviewer 3 is finalized. 03 May 2023 Corresponding Author submitted manuscript , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=31455446726, createdName=ms4000001861684629, createdTime=Sat Jul 01 09:37:31 CST 2023, time=2023-07-01, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2145328, encodeId=91c621453289a, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：中药药理学;药理学;肿瘤药理 经验分享：2023年5.6分，不错，点赞！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:38:18 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2129824, encodeId=9267212982410, content=偏重的研究方向：中药药理 经验分享：请问一般有几个审稿人呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01228365434, createdName=ms5000001535986025, createdTime=Wed May 03 10:58:41 CST 2023, time=2023-05-03, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2108610, encodeId=55da210861019, content=The Associate Editor X is evaluating any revisions made to the manuscript to take a final decision.这个状态需要多久？还会被拒稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50135526541, createdName=ms3000000979708654, createdTime=Tue Jan 03 11:40:19 CST 2023, time=2023-01-03, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2099025, encodeId=bca6209902562, content=请问大家在Editorial Assignment阶段都停留多久呀，我的马上1个月了也没有动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39605645778, createdName=ms3000001177178927, createdTime=Mon Nov 07 18:58:58 CST 2022, time=2022-11-07, status=1, ipAttribution=)]

2023-07-01 ms4000001861684629 来自黑龙江省

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：中药单体
经验分享：历时2个月，4个审稿人，一个拒稿，三个修改后同意。 20 Jun 2023 Article accepted for publication. 16 Jun 2023 Review of Review Editor 3 finalized. 13 Jun 2023 Corresponding Author re-submitted manuscript. 12 Jun 2023 Reviewer 3 posted new comments. 10 Jun 2023 Review of Review Editor 4 finalized. 09 Jun 2023 Review of Review Editor 2 finalized.Review Editor 1 posted new comments.Corresponding Author re-submitted manuscript.You posted new comments.You posted new comments.You posted new comments. 29 May 2023 Editorial Office reminded you to respond to reviewer 3 and/or resubmit your manuscript in the discussion forum. 16 May 2023 Associate Editor reactivated the review of Review Editor 3.Interactive review forum activated. 11 May 2023 Review of Reviewer 3 is finalized. 03 May 2023 Corresponding Author submitted manuscript

65 0

[GetPortalCommentsPageByObjectIdResponse(id=1003537, encodeId=7ed3100353e7d, content=偏重的研究方向：心血管药理学 经验分享：请问朋友们，frontiers in pharmacology这个杂志社需不需要原始数据啊，我的文章现在处于Review Finalized，两个审稿人均已同意收稿，但是编辑提了不少问题。目前为止还未通知我上传原始记录，我想问下会要吗？大概什么时候要？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=38205516444, createdName=若氵离, createdTime=Thu Jul 29 10:20:59 CST 2021, time=2021-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1247445, encodeId=b238124e445bc, content=偏重的研究方向：民族药理学;中药复方 经验分享：投稿第三天就收到上传原始数据的邮箱了。实验结果的原始数据好好，第一次遇到连把数据库下载的原始数据也要提供😄, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=223, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Tue Sep 06 12:10:42 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2133754, encodeId=26252133e54f1, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：综述 经验分享：09 May 2023 Article accepted for publication. 02 May 2023 Review of Review Editor 3 finalized. 28 Apr 2023 Submitting Author posted new comments in the Editor tab. Submitting Author re-submitted manuscript. You posted new comments. 16 Apr 2023 Reviewer 3 posted new comments. 15 Apr 2023 Submitting Author re-submitted manuscript. You posted new comments. Submitting Author posted new comments in the Editor tab. 06 Apr 2023 Interactive review forum activated. 05 Apr 2023 Review of Reviewer 1 is finalized. 04 Apr 2023 Review of Reviewer 2 is finalized. 23 Mar 2023 Submitting Author submitted manuscrip, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64f46563607, createdName=ms1000000861767492, createdTime=Sun May 14 16:38:06 CST 2023, time=2023-05-14, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2148044, encodeId=cfd7214804414, content=审稿速度:2.0 偏重的研究方向：药理 经验分享：从投稿到接收整整两个月，非常顺利的一次投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e82b8691518, createdName=ms2000000241844584, createdTime=Fri Jul 14 17:07:22 CST 2023, time=2023-07-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2146235, encodeId=229a21462355e, content=大佬们，请问接收后多久能在web of science检索到, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=31455446726, createdName=ms4000001861684629, createdTime=Tue Jul 04 08:51:52 CST 2023, time=2023-07-04, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2145782, encodeId=622a2145e828b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：中药单体 经验分享：历时2个月，4个审稿人，一个拒稿，三个修改后同意。 20 Jun 2023 Article accepted for publication. 16 Jun 2023 Review of Review Editor 3 finalized. 13 Jun 2023 Corresponding Author re-submitted manuscript. 12 Jun 2023 Reviewer 3 posted new comments. 10 Jun 2023 Review of Review Editor 4 finalized. 09 Jun 2023 Review of Review Editor 2 finalized.Review Editor 1 posted new comments.Corresponding Author re-submitted manuscript.You posted new comments.You posted new comments.You posted new comments. 29 May 2023 Editorial Office reminded you to respond to reviewer 3 and/or resubmit your manuscript in the discussion forum. 16 May 2023 Associate Editor reactivated the review of Review Editor 3.Interactive review forum activated. 11 May 2023 Review of Reviewer 3 is finalized. 03 May 2023 Corresponding Author submitted manuscript , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=31455446726, createdName=ms4000001861684629, createdTime=Sat Jul 01 09:37:31 CST 2023, time=2023-07-01, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2145328, encodeId=91c621453289a, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：中药药理学;药理学;肿瘤药理 经验分享：2023年5.6分，不错，点赞！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:38:18 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2129824, encodeId=9267212982410, content=偏重的研究方向：中药药理 经验分享：请问一般有几个审稿人呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01228365434, createdName=ms5000001535986025, createdTime=Wed May 03 10:58:41 CST 2023, time=2023-05-03, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2108610, encodeId=55da210861019, content=The Associate Editor X is evaluating any revisions made to the manuscript to take a final decision.这个状态需要多久？还会被拒稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50135526541, createdName=ms3000000979708654, createdTime=Tue Jan 03 11:40:19 CST 2023, time=2023-01-03, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2099025, encodeId=bca6209902562, content=请问大家在Editorial Assignment阶段都停留多久呀，我的马上1个月了也没有动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39605645778, createdName=ms3000001177178927, createdTime=Mon Nov 07 18:58:58 CST 2022, time=2022-11-07, status=1, ipAttribution=)]

2023-06-29 侠胆医心来自香港

审稿速度:2.0 | 投稿命中率:50.0
偏重的研究方向：中药药理学;药理学;肿瘤药理
经验分享：2023年5.6分，不错，点赞！

70 0

[GetPortalCommentsPageByObjectIdResponse(id=1003537, encodeId=7ed3100353e7d, content=偏重的研究方向：心血管药理学 经验分享：请问朋友们，frontiers in pharmacology这个杂志社需不需要原始数据啊，我的文章现在处于Review Finalized，两个审稿人均已同意收稿，但是编辑提了不少问题。目前为止还未通知我上传原始记录，我想问下会要吗？大概什么时候要？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=38205516444, createdName=若氵离, createdTime=Thu Jul 29 10:20:59 CST 2021, time=2021-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1247445, encodeId=b238124e445bc, content=偏重的研究方向：民族药理学;中药复方 经验分享：投稿第三天就收到上传原始数据的邮箱了。实验结果的原始数据好好，第一次遇到连把数据库下载的原始数据也要提供😄, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=223, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Tue Sep 06 12:10:42 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2133754, encodeId=26252133e54f1, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：综述 经验分享：09 May 2023 Article accepted for publication. 02 May 2023 Review of Review Editor 3 finalized. 28 Apr 2023 Submitting Author posted new comments in the Editor tab. Submitting Author re-submitted manuscript. You posted new comments. 16 Apr 2023 Reviewer 3 posted new comments. 15 Apr 2023 Submitting Author re-submitted manuscript. You posted new comments. Submitting Author posted new comments in the Editor tab. 06 Apr 2023 Interactive review forum activated. 05 Apr 2023 Review of Reviewer 1 is finalized. 04 Apr 2023 Review of Reviewer 2 is finalized. 23 Mar 2023 Submitting Author submitted manuscrip, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64f46563607, createdName=ms1000000861767492, createdTime=Sun May 14 16:38:06 CST 2023, time=2023-05-14, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2148044, encodeId=cfd7214804414, content=审稿速度:2.0 偏重的研究方向：药理 经验分享：从投稿到接收整整两个月，非常顺利的一次投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e82b8691518, createdName=ms2000000241844584, createdTime=Fri Jul 14 17:07:22 CST 2023, time=2023-07-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2146235, encodeId=229a21462355e, content=大佬们，请问接收后多久能在web of science检索到, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=31455446726, createdName=ms4000001861684629, createdTime=Tue Jul 04 08:51:52 CST 2023, time=2023-07-04, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2145782, encodeId=622a2145e828b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：中药单体 经验分享：历时2个月，4个审稿人，一个拒稿，三个修改后同意。 20 Jun 2023 Article accepted for publication. 16 Jun 2023 Review of Review Editor 3 finalized. 13 Jun 2023 Corresponding Author re-submitted manuscript. 12 Jun 2023 Reviewer 3 posted new comments. 10 Jun 2023 Review of Review Editor 4 finalized. 09 Jun 2023 Review of Review Editor 2 finalized.Review Editor 1 posted new comments.Corresponding Author re-submitted manuscript.You posted new comments.You posted new comments.You posted new comments. 29 May 2023 Editorial Office reminded you to respond to reviewer 3 and/or resubmit your manuscript in the discussion forum. 16 May 2023 Associate Editor reactivated the review of Review Editor 3.Interactive review forum activated. 11 May 2023 Review of Reviewer 3 is finalized. 03 May 2023 Corresponding Author submitted manuscript , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=31455446726, createdName=ms4000001861684629, createdTime=Sat Jul 01 09:37:31 CST 2023, time=2023-07-01, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2145328, encodeId=91c621453289a, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：中药药理学;药理学;肿瘤药理 经验分享：2023年5.6分，不错，点赞！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:38:18 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2129824, encodeId=9267212982410, content=偏重的研究方向：中药药理 经验分享：请问一般有几个审稿人呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01228365434, createdName=ms5000001535986025, createdTime=Wed May 03 10:58:41 CST 2023, time=2023-05-03, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2108610, encodeId=55da210861019, content=The Associate Editor X is evaluating any revisions made to the manuscript to take a final decision.这个状态需要多久？还会被拒稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50135526541, createdName=ms3000000979708654, createdTime=Tue Jan 03 11:40:19 CST 2023, time=2023-01-03, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2099025, encodeId=bca6209902562, content=请问大家在Editorial Assignment阶段都停留多久呀，我的马上1个月了也没有动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39605645778, createdName=ms3000001177178927, createdTime=Mon Nov 07 18:58:58 CST 2022, time=2022-11-07, status=1, ipAttribution=)]

2023-05-03 ms5000001535986025 来自福建省

偏重的研究方向：中药药理
经验分享：请问一般有几个审稿人呀

0 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1003537, encodeId=7ed3100353e7d, content=偏重的研究方向：心血管药理学 经验分享：请问朋友们，frontiers in pharmacology这个杂志社需不需要原始数据啊，我的文章现在处于Review Finalized，两个审稿人均已同意收稿，但是编辑提了不少问题。目前为止还未通知我上传原始记录，我想问下会要吗？大概什么时候要？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=38205516444, createdName=若氵离, createdTime=Thu Jul 29 10:20:59 CST 2021, time=2021-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1247445, encodeId=b238124e445bc, content=偏重的研究方向：民族药理学;中药复方 经验分享：投稿第三天就收到上传原始数据的邮箱了。实验结果的原始数据好好，第一次遇到连把数据库下载的原始数据也要提供😄, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=223, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Tue Sep 06 12:10:42 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2133754, encodeId=26252133e54f1, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：综述 经验分享：09 May 2023 Article accepted for publication. 02 May 2023 Review of Review Editor 3 finalized. 28 Apr 2023 Submitting Author posted new comments in the Editor tab. Submitting Author re-submitted manuscript. You posted new comments. 16 Apr 2023 Reviewer 3 posted new comments. 15 Apr 2023 Submitting Author re-submitted manuscript. You posted new comments. Submitting Author posted new comments in the Editor tab. 06 Apr 2023 Interactive review forum activated. 05 Apr 2023 Review of Reviewer 1 is finalized. 04 Apr 2023 Review of Reviewer 2 is finalized. 23 Mar 2023 Submitting Author submitted manuscrip, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64f46563607, createdName=ms1000000861767492, createdTime=Sun May 14 16:38:06 CST 2023, time=2023-05-14, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2148044, encodeId=cfd7214804414, content=审稿速度:2.0 偏重的研究方向：药理 经验分享：从投稿到接收整整两个月，非常顺利的一次投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e82b8691518, createdName=ms2000000241844584, createdTime=Fri Jul 14 17:07:22 CST 2023, time=2023-07-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2146235, encodeId=229a21462355e, content=大佬们，请问接收后多久能在web of science检索到, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=31455446726, createdName=ms4000001861684629, createdTime=Tue Jul 04 08:51:52 CST 2023, time=2023-07-04, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2145782, encodeId=622a2145e828b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：中药单体 经验分享：历时2个月，4个审稿人，一个拒稿，三个修改后同意。 20 Jun 2023 Article accepted for publication. 16 Jun 2023 Review of Review Editor 3 finalized. 13 Jun 2023 Corresponding Author re-submitted manuscript. 12 Jun 2023 Reviewer 3 posted new comments. 10 Jun 2023 Review of Review Editor 4 finalized. 09 Jun 2023 Review of Review Editor 2 finalized.Review Editor 1 posted new comments.Corresponding Author re-submitted manuscript.You posted new comments.You posted new comments.You posted new comments. 29 May 2023 Editorial Office reminded you to respond to reviewer 3 and/or resubmit your manuscript in the discussion forum. 16 May 2023 Associate Editor reactivated the review of Review Editor 3.Interactive review forum activated. 11 May 2023 Review of Reviewer 3 is finalized. 03 May 2023 Corresponding Author submitted manuscript , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=31455446726, createdName=ms4000001861684629, createdTime=Sat Jul 01 09:37:31 CST 2023, time=2023-07-01, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2145328, encodeId=91c621453289a, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：中药药理学;药理学;肿瘤药理 经验分享：2023年5.6分，不错，点赞！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:38:18 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2129824, encodeId=9267212982410, content=偏重的研究方向：中药药理 经验分享：请问一般有几个审稿人呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01228365434, createdName=ms5000001535986025, createdTime=Wed May 03 10:58:41 CST 2023, time=2023-05-03, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2108610, encodeId=55da210861019, content=The Associate Editor X is evaluating any revisions made to the manuscript to take a final decision.这个状态需要多久？还会被拒稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50135526541, createdName=ms3000000979708654, createdTime=Tue Jan 03 11:40:19 CST 2023, time=2023-01-03, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2099025, encodeId=bca6209902562, content=请问大家在Editorial Assignment阶段都停留多久呀，我的马上1个月了也没有动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39605645778, createdName=ms3000001177178927, createdTime=Mon Nov 07 18:58:58 CST 2022, time=2022-11-07, status=1, ipAttribution=)]

2023-01-03 ms3000000979708654 来自陕西省

The Associate Editor X is evaluating any revisions made to the manuscript to take a final decision.这个状态需要多久？还会被拒稿吗？

79 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=1003537, encodeId=7ed3100353e7d, content=偏重的研究方向：心血管药理学 经验分享：请问朋友们，frontiers in pharmacology这个杂志社需不需要原始数据啊，我的文章现在处于Review Finalized，两个审稿人均已同意收稿，但是编辑提了不少问题。目前为止还未通知我上传原始记录，我想问下会要吗？大概什么时候要？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=38205516444, createdName=若氵离, createdTime=Thu Jul 29 10:20:59 CST 2021, time=2021-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1247445, encodeId=b238124e445bc, content=偏重的研究方向：民族药理学;中药复方 经验分享：投稿第三天就收到上传原始数据的邮箱了。实验结果的原始数据好好，第一次遇到连把数据库下载的原始数据也要提供😄, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=223, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Tue Sep 06 12:10:42 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2133754, encodeId=26252133e54f1, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：综述 经验分享：09 May 2023 Article accepted for publication. 02 May 2023 Review of Review Editor 3 finalized. 28 Apr 2023 Submitting Author posted new comments in the Editor tab. Submitting Author re-submitted manuscript. You posted new comments. 16 Apr 2023 Reviewer 3 posted new comments. 15 Apr 2023 Submitting Author re-submitted manuscript. You posted new comments. Submitting Author posted new comments in the Editor tab. 06 Apr 2023 Interactive review forum activated. 05 Apr 2023 Review of Reviewer 1 is finalized. 04 Apr 2023 Review of Reviewer 2 is finalized. 23 Mar 2023 Submitting Author submitted manuscrip, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64f46563607, createdName=ms1000000861767492, createdTime=Sun May 14 16:38:06 CST 2023, time=2023-05-14, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2148044, encodeId=cfd7214804414, content=审稿速度:2.0 偏重的研究方向：药理 经验分享：从投稿到接收整整两个月，非常顺利的一次投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e82b8691518, createdName=ms2000000241844584, createdTime=Fri Jul 14 17:07:22 CST 2023, time=2023-07-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2146235, encodeId=229a21462355e, content=大佬们，请问接收后多久能在web of science检索到, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=31455446726, createdName=ms4000001861684629, createdTime=Tue Jul 04 08:51:52 CST 2023, time=2023-07-04, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2145782, encodeId=622a2145e828b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：中药单体 经验分享：历时2个月，4个审稿人，一个拒稿，三个修改后同意。 20 Jun 2023 Article accepted for publication. 16 Jun 2023 Review of Review Editor 3 finalized. 13 Jun 2023 Corresponding Author re-submitted manuscript. 12 Jun 2023 Reviewer 3 posted new comments. 10 Jun 2023 Review of Review Editor 4 finalized. 09 Jun 2023 Review of Review Editor 2 finalized.Review Editor 1 posted new comments.Corresponding Author re-submitted manuscript.You posted new comments.You posted new comments.You posted new comments. 29 May 2023 Editorial Office reminded you to respond to reviewer 3 and/or resubmit your manuscript in the discussion forum. 16 May 2023 Associate Editor reactivated the review of Review Editor 3.Interactive review forum activated. 11 May 2023 Review of Reviewer 3 is finalized. 03 May 2023 Corresponding Author submitted manuscript , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=31455446726, createdName=ms4000001861684629, createdTime=Sat Jul 01 09:37:31 CST 2023, time=2023-07-01, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2145328, encodeId=91c621453289a, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：中药药理学;药理学;肿瘤药理 经验分享：2023年5.6分，不错，点赞！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:38:18 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2129824, encodeId=9267212982410, content=偏重的研究方向：中药药理 经验分享：请问一般有几个审稿人呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01228365434, createdName=ms5000001535986025, createdTime=Wed May 03 10:58:41 CST 2023, time=2023-05-03, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2108610, encodeId=55da210861019, content=The Associate Editor X is evaluating any revisions made to the manuscript to take a final decision.这个状态需要多久？还会被拒稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50135526541, createdName=ms3000000979708654, createdTime=Tue Jan 03 11:40:19 CST 2023, time=2023-01-03, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2099025, encodeId=bca6209902562, content=请问大家在Editorial Assignment阶段都停留多久呀，我的马上1个月了也没有动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39605645778, createdName=ms3000001177178927, createdTime=Mon Nov 07 18:58:58 CST 2022, time=2022-11-07, status=1, ipAttribution=)]

2022-11-07 ms3000001177178927

请问大家在Editorial Assignment阶段都停留多久呀，我的马上1个月了也没有动静

119 6

展开6条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务